Sana Biotechnology to present UP421 data at EASD 2026
Sana Biotechnology, Inc. (NASDAQ: SANA) announced it will present clinical data from an investigator-sponsored, first-in-human study of UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune platform (HIP) technology, at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan, Italy. The study evaluates the therapy in a type 1 diabetes patient without immunosuppression, aiming to reduce immune rejection risks.
*this image is generated using AI for illustrative purposes only.
Sana Biotechnology, Inc. (NASDAQ: SANA) will present clinical data from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune platform (HIP) technology, into a patient with type 1 diabetes without immunosuppression. The presentation will take place at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026, scheduled from September 28 to October 2, 2026, in Milan, Italy. The symposium will highlight data from the study, which evaluates the use of UP421 in a type 1 diabetes patient without the need for immunosuppression. This approach leverages Sana’s HIP technology to engineer allogeneic primary islet cells, aiming to reduce immune rejection risks.
Key Details of the Presentation
| Aspect | Details |
|---|---|
| Therapy | UP421 |
| Technology | Hypoimmune platform (HIP) |
| Condition | Type 1 diabetes |
| Immunosuppression | Not required |
| Study Type | Investigator-sponsored, first-in-human |
The EASD Annual Meeting 2026 will provide a platform for discussing the clinical implications of this study. Sana’s focus on engineered cells aims to address unmet medical needs in diabetes treatment.
What are the potential regulatory pathways for UP421 if the first-in-human data shows efficacy without immunosuppression?
How might the elimination of immunosuppression requirements impact patient adoption and market positioning compared to current cell therapies?
What are the scalability challenges for manufacturing UP421 if the therapy progresses to late-stage clinical trials?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
